157 related articles for article (PubMed ID: 31585951)
1. Identification of a tumor-specific allo-HLA-restricted γδTCR.
Kierkels GJJ; Scheper W; Meringa AD; Johanna I; Beringer DX; Janssen A; Schiffler M; Aarts-Riemens T; Kramer L; Straetemans T; Heijhuurs S; Leusen JHW; San José E; Fuchs K; Griffioen M; Falkenburg JH; Bongiovanni L; de Bruin A; Vargas-Diaz D; Altelaar M; Heck AJR; Shultz LD; Ishikawa F; Nishimura MI; Sebestyén Z; Kuball J
Blood Adv; 2019 Oct; 3(19):2870-2882. PubMed ID: 31585951
[TBL] [Abstract][Full Text] [Related]
2. Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control.
Johanna I; Hernández-López P; Heijhuurs S; Scheper W; Bongiovanni L; de Bruin A; Beringer DX; Oostvogels R; Straetemans T; Sebestyen Z; Kuball J
Front Immunol; 2021; 12():752699. PubMed ID: 34759930
[TBL] [Abstract][Full Text] [Related]
3. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice.
Johanna I; Hernández-López P; Heijhuurs S; Bongiovanni L; de Bruin A; Beringer D; van Dooremalen S; Shultz LD; Ishikawa F; Sebestyen Z; Straetemans T; Kuball J
J Leukoc Biol; 2020 Jun; 107(6):1069-1079. PubMed ID: 32022317
[TBL] [Abstract][Full Text] [Related]
4. The avidity of cross-reactive virus-specific T cells for their viral and allogeneic epitopes is variable and depends on epitope expression.
van den Heuvel H; Heutinck KM; van der Meer-Prins EMW; Franke-van Dijk MEI; van Miert PPMC; Zhang X; Ten Berge IJM; Claas FHJ
Hum Immunol; 2018 Jan; 79(1):39-50. PubMed ID: 29100943
[TBL] [Abstract][Full Text] [Related]
5. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
6. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
[TBL] [Abstract][Full Text] [Related]
7. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
[TBL] [Abstract][Full Text] [Related]
10. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
11. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
12. Unusual Placement of an EBV Epitope into the Groove of the Ankylosing Spondylitis-Associated HLA-B27 Allele Allows CD8+ T Cell Activation.
Tedeschi V; Alba J; Paladini F; Paroli M; Cauli A; Mathieu A; Sorrentino R; D'Abramo M; Fiorillo MT
Cells; 2019 Jun; 8(6):. PubMed ID: 31212633
[TBL] [Abstract][Full Text] [Related]
13. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
14. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
[TBL] [Abstract][Full Text] [Related]
15. CD8+ T cells are necessary for recognition of allelic, but not locus-mismatched or xeno-, HLA class I transplantation antigens.
Borenstein SH; Graham J; Zhang XL; Chamberlain JW
J Immunol; 2000 Sep; 165(5):2341-53. PubMed ID: 10946256
[TBL] [Abstract][Full Text] [Related]
16. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells.
Kobayashi H; Kimura S; Aoki N; Sato K; Celis E; Katagiri M
Immunogenetics; 2001 Oct; 53(8):626-33. PubMed ID: 11797095
[TBL] [Abstract][Full Text] [Related]
17. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
18. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
[TBL] [Abstract][Full Text] [Related]
19. Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.
Harris DT; Hager MV; Smith SN; Cai Q; Stone JD; Kruger P; Lever M; Dushek O; Schmitt TM; Greenberg PD; Kranz DM
J Immunol; 2018 Feb; 200(3):1088-1100. PubMed ID: 29288199
[TBL] [Abstract][Full Text] [Related]
20. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
